ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HBM7020

A development code.

Its studies are mostly in Arthritis, Rheumatoid, led by Otsuka.

Furthest: phase 1, since Jun 11, 20261 company-led study, 1 open or runningNext primary completion: Nov 20, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka11 open or runningphase 1since Jun 11, 2026Jun 11, 2026Nov 20, 2028phase 1 · NCT07649265

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 11, 2026First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT07649265 · 63 planned · Australia

Ahead

  1. Nov 20, 2028Primary completion: phase 1 study in Arthritis, RheumatoidNCT07649265

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07649265Arthritis, Rheumatoid · Australia1RecruitingNov 20, 202863

How it is read

Names in the registry

  • “HBM7020”, 1 entry

Codes read as this program: HBM7020.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.